Skip to main
IMUX

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic is developing a promising pipeline of oral immunology therapies for chronic inflammatory and autoimmune diseases, which have a high unmet medical need. The company's lead candidate, IMU-838, has shown impressive results in clinical trials for multiple sclerosis and has the potential to capture significant market share in the relapsing forms of the disease. Additionally, the company's financial position is strong with enough cash to support operations into late 2027, providing potential for long-term growth and success.

Bears say

Immunic is currently developing several potential treatments for chronic inflammatory and autoimmune diseases, but their lead asset, vidofludimus calcium, has shown only modest benefits in clinical trials against RMS, and we anticipate this will limit its market potential among a highly competitive landscape. The company's recent financing, while providing a runway into 2027, may also indicate a lack of confidence in the potential of their pipeline. Additionally, we have concerns about the limited cash reserves prior to the financing, indicating the capital-intensive nature of their late-stage program.

Immunic Inc (IMUX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.